Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia.
Majority of HIV-2-infected individuals meet the criteria of long-term non-progressors. This has been linked to superior qualitative HIV-2-specific cellular immune responses that correlate with viral control. However, it is unknown whether this is due to frequent targeting of immunodominant Gag epito...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1797050448554754048 |
|---|---|
| author | Ondondo, B Rowland-Jones, S Dorrell, L Peterson, K Cotten, M Whittle, H Jaye, A |
| author_facet | Ondondo, B Rowland-Jones, S Dorrell, L Peterson, K Cotten, M Whittle, H Jaye, A |
| author_sort | Ondondo, B |
| collection | OXFORD |
| description | Majority of HIV-2-infected individuals meet the criteria of long-term non-progressors. This has been linked to superior qualitative HIV-2-specific cellular immune responses that correlate with viral control. However, it is unknown whether this is due to frequent targeting of immunodominant Gag epitopes in HIV-2 than HIV-1 infection. We describe a comprehensive comparison of the magnitude, breadth and frequency of Gag responses and the degree of cross-recognition of frequently targeted, immunodominant Gag peptides in a cross-sectional study of asymptomatic HIV-1- and HIV-2-infected individuals. Fresh PBMC from 20 HIV-1- and 20 HIV-2-infected patients with similar CD4(+) T-cell counts (p=0.36) were stimulated with pools of HIV-1 and/or HIV-2 Gag peptides in an IFN-gamma ELISPOT assay. We found no difference in the cumulative magnitude of IFN-gamma responses (p=0.75) despite significantly lower plasma viral loads in HIV-2-infected people (p<0.0001). However, Gag211-290 was targeted with significantly higher magnitude in HIV-2-infected subjects (p=0.03) although this did not correlate with viral control. There was no difference in frequently targeted Gag peptides, the breadth, immunodominance or cross-recognition of Gag peptide pools between the two infections. This suggests that other factors may control viral replication in HIV-2 infection. |
| first_indexed | 2024-03-06T18:05:18Z |
| format | Journal article |
| id | oxford-uuid:013e1f1e-ac97-4202-a4d3-951604afff5d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:05:18Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:013e1f1e-ac97-4202-a4d3-951604afff5d2022-03-26T08:33:49ZComprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:013e1f1e-ac97-4202-a4d3-951604afff5dEnglishSymplectic Elements at Oxford2008Ondondo, BRowland-Jones, SDorrell, LPeterson, KCotten, MWhittle, HJaye, AMajority of HIV-2-infected individuals meet the criteria of long-term non-progressors. This has been linked to superior qualitative HIV-2-specific cellular immune responses that correlate with viral control. However, it is unknown whether this is due to frequent targeting of immunodominant Gag epitopes in HIV-2 than HIV-1 infection. We describe a comprehensive comparison of the magnitude, breadth and frequency of Gag responses and the degree of cross-recognition of frequently targeted, immunodominant Gag peptides in a cross-sectional study of asymptomatic HIV-1- and HIV-2-infected individuals. Fresh PBMC from 20 HIV-1- and 20 HIV-2-infected patients with similar CD4(+) T-cell counts (p=0.36) were stimulated with pools of HIV-1 and/or HIV-2 Gag peptides in an IFN-gamma ELISPOT assay. We found no difference in the cumulative magnitude of IFN-gamma responses (p=0.75) despite significantly lower plasma viral loads in HIV-2-infected people (p<0.0001). However, Gag211-290 was targeted with significantly higher magnitude in HIV-2-infected subjects (p=0.03) although this did not correlate with viral control. There was no difference in frequently targeted Gag peptides, the breadth, immunodominance or cross-recognition of Gag peptide pools between the two infections. This suggests that other factors may control viral replication in HIV-2 infection. |
| spellingShingle | Ondondo, B Rowland-Jones, S Dorrell, L Peterson, K Cotten, M Whittle, H Jaye, A Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title | Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title_full | Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title_fullStr | Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title_full_unstemmed | Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title_short | Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia. |
| title_sort | comprehensive analysis of hiv gag specific ifn gamma response in hiv 1 and hiv 2 infected asymptomatic patients from a clinical cohort in the gambia |
| work_keys_str_mv | AT ondondob comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT rowlandjoness comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT dorrelll comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT petersonk comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT cottenm comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT whittleh comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia AT jayea comprehensiveanalysisofhivgagspecificifngammaresponseinhiv1andhiv2infectedasymptomaticpatientsfromaclinicalcohortinthegambia |